Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Quite a great proportion of known tumor cells carry mutation in TP53 gene, expressing mutant p53 proteins (mutp53) missing not only original genome protective activities but also acquiring gain-of-functions that favor tumor progression and impede treatment of cancers. Zinc ions were reported as agents cytocidal to mutp53-carrying cells by recovering p53 normal functions and abrogating mutp53. Meanwhile in a hyperthermia scenario, the function of wild type p53 is required to ablate tumors upon heat treatment hence the effects might be hindered in a mutp53 background. We herein synthesized zinc-doped Prussian blue (ZP) nanoparticles (NPs) to combine Zn 2+ based and photothermal therapeutic effects. An efficient release of Zn 2+ in a glutathione-enriched tumor intracellular microenvironment and a prominent photothermal conversion manifested ZP NPs as zinc ion carriers and photothermal agents. Apoptotic death and autophagic mutp53 elimination were found to be induced by ZP NPs in R280K mutp53-containing MDA-MB-231 cells and hyperthermia was rendered to ameliorate the treatment in vitro through further mutp53 elimination and increased cell death. The combinatorial therapeutic effect was also confirmed in vivo in a mouse model. This study might expand zinc delivery carriers and shed a light on potential interplay of hyperthermia and mutp53 degradation in cancer treatment. The combinational effects of ion interference and photothermal treatment of ZP NPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zn2+ plays an important role in p53-DNA recognition and enhances the interaction between p53 and DNA.354”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [354]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145
Research works printed but not linked: 46
- Vousden, 2007, p53 in health and disease, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
- Joerger, 2016, The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches, Annu Rev Biochem, 85, 375, 10.1146/annurev-biochem-060815-014710 · DOI · Paper page
- Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 10.1038/358015a0 · DOI · Paper page
- Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
- Dolgin, 2017, The most popular genes in the human genome, Nature, 551, 427, 10.1038/d41586-017-07291-9 · DOI
- Schulz-Heddergott, 2018, Gain-of-Function (GOF) mutant p53 as actionable therapeutic target, Cancers, 10, 10.3390/cancers10060188 · DOI · Paper page
- Zhang, 2020, Gain-of-function mutant p53 in cancer progression and therapy, J Mol Cell Biol, 12, 674, 10.1093/jmcb/mjaa040 · DOI · Paper page
- Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev, 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Muller, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038/ncb2641 · DOI · Paper page
- Bossi, 2006, Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression, Oncogene, 25, 304, 10.1038/sj.onc.1209026 · DOI · Paper page
- Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
- Yan, 2011, Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression, J Biol Chem, 286, 17478, 10.1074/jbc.M111.231639 · DOI · Paper page
- Parrales, 2016, DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway, Nat Cell Biol, 18, 1233, 10.1038/ncb3427 · DOI · Paper page
- Zhang, 2015, Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53, Cancer Res, 75, 3842, 10.1158/0008-5472.CAN-13-1079 · DOI · Paper page
- Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
- Proia, 2014, Ganetespib and HSP90: translating preclinical hypotheses into clinical promise, Cancer Res, 74, 1294, 10.1158/0008-5472.CAN-13-3263 · DOI · Paper page
- Padmanabhan, 2018, USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells, Nat Commun, 9, 1270, 10.1038/s41467-018-03599-w · DOI · Paper page
- Foggetti, 2019, Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival, Biosci Rep, 39, 10.1042/BSR20181345 · DOI · Paper page
- Foggetti, 2017, Gambogic acid counteracts mutant p53 stability by inducing autophagy, Biochim Biophys Acta Mol Cell Res, 1864, 382, 10.1016/j.bbamcr.2016.11.023 · DOI
- Garufi, 2016, Reactivation of mutant p53 by capsaicin, the major constituent of peppers, J Exp Clin Cancer Res, 35, 136, 10.1186/s13046-016-0417-9 · DOI
- Loh, 2010, The missing zinc: p53 misfolding and cancer, Metallomics, 2, 442, 10.1039/c003915b · DOI · Paper page
- Meplan, 2000, Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells, Oncogene, 19, 5227, 10.1038/sj.onc.1203907 · DOI · Paper page
- Puca, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161/cc.10.10.15642 · DOI · Paper page
- Garufi, 2014, Degradation of mutant p53H175 protein by Zn(II) through autophagy, Cell Death Dis, 5, e1271, 10.1038/cddis.2014.217 · DOI · Paper page
- Liu, 2021, Cancer therapeutic strategies based on metal ions, Chem Sci, 12, 12234, 10.1039/D1SC03516A · DOI
- Setyawati, 2013, Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway, Biomaterials, 34, 10133, 10.1016/j.biomaterials.2013.09.024 · DOI
- Garufi, 2013, A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells, J Exp Clin Cancer Res, 32, 72, 10.1186/1756-9966-32-72 · DOI · Paper page
- Garufi, 2020, Interplay between endoplasmic reticulum (ER) stress and autophagy induces mutant p53H273 degradation, Biomolecules, 10, 10.3390/biom10030392 · DOI
- Qian, 2020, Enhancing chemotherapy of p53-mutated cancer through ubiquitination-dependent proteasomal degradation of mutant p53 proteins by engineered ZnFe-4 nanoparticles, Adv Funct Mater, 30, 10.1002/adfm.202001994 · DOI
- Zhang, 2021, Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8, Biomaterials, 271, 10.1016/j.biomaterials.2021.120720 · DOI
- Beik, 2016, Nanotechnology in hyperthermia cancer therapy: from fundamental principles to advanced applications, J Control Release, 235, 205, 10.1016/j.jconrel.2016.05.062 · DOI · Paper page
- Ohnishi, 2001, Heat-induced p53-dependent signal transduction and its role in hyperthermic cancer therapy, Int J Hyperthermia, 17, 415, 10.1080/02656730110063604 · DOI
- Wang, 2014, Novel insights into combating cancer chemotherapy resistance using a plasmonic nanocarrier: enhancing drug sensitiveness and accumulation simultaneously with localized mild photothermal stimulus of femtosecond pulsed laser, Adv Funct Mater, 24, 4229, 10.1002/adfm.201400015 · DOI
- Shokouhimehr, 2010, Dual purpose Prussian blue nanoparticles for cellular imaging and drug delivery: a new generation of T1-weighted MRI contrast and small molecule delivery agents, J Mater Chem, 20, 10.1039/b923184f · DOI · Paper page
- Aaseth, 2019, Medical therapy of patients contaminated with radioactive cesium or iodine, Biomolecules, 9, 10.3390/biom9120856 · doi:10.3390/biom9120856
- Wang, 2020, Multifunctional Prussian blue-based nanomaterials: preparation, modification, and theranostic applications, Coord Chem Rev, 419
- Fu, 2012, Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer therapy, Chem Commun, 48, 11567, 10.1039/c2cc36456e · DOI · Paper page
- Wu, 2020, Copper-enriched prussian blue nanomedicine for in situ disulfiram toxification and photothermal antitumor amplification, Adv Mater, 32, 10.1002/adma.202000542 · DOI · Paper page
- Zuo, 2022, Copper-based theranostic nanocatalysts for synergetic photothermal-chemodynamic therapy, Acta Biomater, 10.1016/j.actbio.2022.05.030 · doi:10.1016/j.actbio.2022.05.030
- Chen, 2020, Tumor-microenvironment-triggered ion exchange of a metal-organic framework hybrid for multimodal imaging and synergistic therapy of tumors, Adv Mater, 32, 10.1002/adma.202001452 · DOI
- Buser, 1977, The crystal structure of Prussian Blue: Fe4[Fe(CN)6]3.xH2O, Inorg Chem, 16, 2704, 10.1021/ic50177a008 · DOI · Paper page
- Li, 2019, Zinc-doped Prussian blue enhances photothermal clearance of Staphylococcus aureus and promotes tissue repair in infected wounds, Nat Commun, 10, 4490, 10.1038/s41467-019-12429-6 · DOI · Paper page
- Schafer, 2001, Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple, Free Radic Biol Med, 30, 1191, 10.1016/S0891-5849(01)00480-4 · DOI · Paper page
- Fuhr, 1973, Nuclear magnetic resonance studies of the solution chemistry of metal complexes. IX. The binding of cadmium, zinc, lead, and mercury by glutathione, J Am Chem Soc, 95, 6944, 10.1021/ja00802a013 · DOI · Paper page
- Choudhury, 2013, Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?, Cell Cycle, 12, 1022, 10.4161/cc.24128 · DOI · Paper page
- He, 2020, Smart gold nanocages for mild heat-triggered drug release and breaking chemoresistance, J Control Release, 323, 387, 10.1016/j.jconrel.2020.04.029 · DOI
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Jin, Q., Zuo, W., Lin, Q., Wu, T., Liu, C., Liu, N., Liu, J., & Zhu, X.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 17
- Issue
- 5
- Pages
- 767-777
- ISSN
- 1818-0876
- Cited by
- 8
- References
- 5
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 11 d)
- Funders
- National Natural Science Foundation of China (81772278)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy. https://app.cochat.ai/papers/10.1016/j.ajps.2022.07.003
- The paper
- Jin, Q., Zuo, W., Lin, Q., Wu, T., Liu, C., Liu, N., Liu, J., & Zhu, X. (2022). Zinc-doped Prussian blue nanoparticles for mutp53-carrying tumor ion interference and photothermal therapy. Asian Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ajps.2022.07.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.